(redirected from Butorphanol tartrate)
Also found in: Medical, Acronyms.
Related to Butorphanol tartrate: Stadol


A synthetic opioid drug, C21H29NO2, given by injection or nasal spray in its tartrate form to treat pain and to supplement anesthesia.

[but(yl) + (m)orph(in)an, structural basis of a group of opioids; see dextromethorphan + -ol.]
References in periodicals archive ?
Once the periocular tissues were well demarcated (13 days after admission), the kestrel was premedicated with butorphanol tartrate (1 mg/kg IM) and midazolam (0.
This study evaluated an aseptic, preservative-free butorphanol tartrate formulation administered using a disposable unit dose spray pump.
Butorphanol tartrate injection is used for pain management, and can be administered intravenously or intramuscularly in three dosage configurations -- 1 mg, 2 mg and 4 mg per vial.
1) Butorphanol tartrate (Torbugesic, Fort Dodge Animal Health, Fort Dodge, IA, USA) has been shown to act by binding [kappa] opioid receptors in the peripheral and central nervous systems and mimicking the activities of endogenous opioids.
6-9) Butorphanol tartrate was found to provide analgesia in African grey parrots (Psittacus erithacus) and Hispaniolan Amazon parrots (Amazona ventralis); for preoperative or postoperative analgesia, the recommended dose was 1-3 mg/kg IM.
The Company utilizes its proprietary STA-T(TM) process to administer intranasally for systemic effect a portfolio of drugs for indications that are mediated through the central nervous system, including scopolamine hydrobromide for the prevention and treatment of motion sickness, apomorphine hydrochloride for the treatment of sexual dysfunction, morphine for treatment of moderate-to-severe pain, including breakthrough pain, and butorphanol tartrate for treatment of migraine pain.
Nastech Pharmaceutical Company Inc (Nasdaq: NSTK) today announced the results of pilot Phase I studies of an intranasal formulation that improves the nasal absorption of butorphanol tartrate, the active ingredient in Stadol NS(R).
Drowsiness and dizziness related to the use of butorphanol tartrate may impair mental and/or physical abilities required for the performance of potentially hazardous tasks, such as driving or operating machinery.
Abboud has found that the benefits of providing postoperative pain relief with butorphanol tartrate nasal spray are compatible with the AHCPR goals.